Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Uterine Neoplasms 1 HER2/Neu Negative 1 Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Paclitaxel 6 pembrolizumab 3 Cisplatin 3 Carboplatin 3 Biopsy 3 adavosertib 2 Trastuzumab 2 Magnetic Resonance Spectroscopy 2 Fulvestrant 2 Doxorubicin 2 ulixertinib 1 tucatinib 1 trastuzumab deruxtecan 1 trastuzumab biosimilar HLX02 1 trametinib 1 selinexor 1 sapanisertib 1 sacituzumab govitecan 1 relugolix 1 relatlimab 1 pertuzumab 1 palbociclib 1 osimertinib 1 omipalisib 1 niraparib 1 larotrectinib 1 ipatasertib 1 erdafitinib 1 dostarlimab 1 dehydroftorafur 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Uterine Neoplasms × 16-fluoroestradiol × 1 year × Clear all

NCT05916196 2026-06-05

[18F]FES PET/.CT in Uterine Cancer

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡